Notice 27 Jun 2025 fda, certification, regulatory compliance, third-party audits, food safety, import/export

🥗FDA Notice on Third-Party Certification for Food Safety Audits

The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection requirements for the accreditation of third-party certification bodies to conduct food safety audits and issue certifications.

Learn More
Notice 27 Jun 2025 business opportunities, indian health service, health services, healthcare expansion, tribal health, kansas, regulatory compliance, missouri, nebraska

🏥PRC Delivery Area Redesignation for Sac and Fox Nation

Notice is hereby given that the Indian Health Service (IHS) has decided to expand the geographic boundaries of the Purchased/ Referred Care Delivery Area (PRCDA) for the Sac and Fox Nation of Missouri in Kansas and Nebraska (Sac and Fox Nation of Missouri or Tribe) to include the counties of Doniphan and Jackson in the State of Kansas, and Holt in the State of Missouri. The final PRCDA for the Sac and Fox Nation of Missouri now includes the following counties: Brown, Doniphan, and Jackson in the State of Kansas; Holt in the State of Missouri; and Richardson in the State of Nebraska. The sole purpose of this expansion is to authorize additional Sac and Fox Nation of Missouri Tribal members and beneficiaries to receive Purchased/Referred Care (PRC) services.

Learn More
Notice 27 Jun 2025 infrastructure, kitsap transit, regulatory compliance, environmental impact, seattle, transportation

🚢Environmental Impact Statement for Kitsap Transit Fast Ferry Terminal

The Federal Transit Administration (FTA), as Federal lead agency, and Kitsap Transit, as local project sponsor and joint lead agency, issue this notice to advise the public that they intend to prepare an environmental impact statement (EIS) pursuant to the National Environmental Policy Act (NEPA) for the Kitsap Transit Fast Ferry Terminal Project (Project) located in the City of Seattle, King County, Washington. The Project would construct a new fast ferry terminal on the downtown Seattle waterfront in order to expand passenger-only ferry (POF) terminal facility capacity.

Learn More
Notice 27 Jun 2025 nscc, operational risk, cybersecurity, regulatory compliance, financial markets, securities exchange

⚖️Proposed Rule Change to Disruption Rules by NSCC

The Securities and Exchange Commission has published a notice concerning the proposed amendment to the Disruption Rules of the National Securities Clearing Corporation. This amendment aims to update critical definitions and streamline operational procedures affecting security transactions, with the goal of enhancing compliance and risk management practices within financial markets.

Learn More
Notice 27 Jun 2025 florida, noaa, scientific research, endangered species, regulatory compliance, marine biology

🐢Notice on Endangered Sea Turtle Research Permit Application

Notice is hereby given that Mariana Fuentes, Ph.D., Florida State University, 3263 Foley Drive, Tallahassee, FL 32309, has applied in due form for a permit to take green (Chelonia mydas), Kemp's ridley (Lepidochelys kempii), hawksbill (Eretmochelys imbricata), and loggerhead (Caretta caretta) sea turtles for purposes of scientific research.

Learn More
Notice 26 Jun 2025 regulatory compliance, healthcare, california, dea, drug enforcement, medical licensing

🚫DEA Revokes Registration of Dr. Bohdan Olesnicky

The Drug Enforcement Administration has revoked the DEA registration of Dr. Bohdan Olesnicky due to his lack of authority to practice medicine in California, following his voluntary surrender of his medical license. This action highlights the necessity for healthcare professionals to maintain state licensure to manage controlled substances legally under federal law.

Learn More
Rule 26 Jun 2025 regulatory compliance, fda, radiation protection, medical devices, x-rays, radiology, x-ray

💉FDA Classifies X-Ray Attenuation Cream Under Class II Devices

The Food and Drug Administration (FDA, the Agency, or we) is classifying the cream for x-ray attenuation into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the cream for x-ray attenuation's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

Learn More
Notice 26 Jun 2025 regulatory compliance, securities and exchange commission, investment companies, co-investment, business development companies

📈SEC Notice for Joint Investment Applications by BDCs

The SEC has issued a notice regarding an application for an order that allows certain business development companies and closed-end management investment companies to co-invest in portfolio companies. The application aims to permit joint transactions typically prohibited by regulations under the Investment Company Act of 1940. Interested parties may request a hearing regarding this application.

Learn More
Notice 26 Jun 2025 regulatory compliance, information collection, financial regulations, commodity futures trading, swap dealers

📊CFTC Notice on Information Collection and Regulatory Impact

In compliance with the Paperwork Reduction Act of 1995 ("PRA"), this notice announces that the Information Collection Request ("ICR") abstracted below has been forwarded to the Office of Information and Regulatory Affairs ("OIRA"), of the Office of Management and Budget ("OMB"), for review and comment. The ICR describes the nature of the information collection and its expected costs and burden.

Learn More
Notice 26 Jun 2025 regulatory compliance, fda, drug development, pharmaceutical industry, lyme disease

💊FDA Guidance on Developing Drugs for Early Lyme Disease Treatment

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment." The purpose of this guidance is to assist sponsors in the clinical development of drugs for the treatment of early Lyme disease as manifested by erythema migrans (EM). This guidance finalizes the draft guidance of the same name issued on February 1, 2023.

Learn More